search
Back to results

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS) (PREVENT-MINS)

Primary Purpose

Myocardial Injury After Noncardiac Surgery (MINS), Myocardial Ischemia

Status
Recruiting
Phase
Phase 3
Locations
Poland
Study Type
Interventional
Intervention
Ivabradine
Placebo
Sponsored by
Jagiellonian University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myocardial Injury After Noncardiac Surgery (MINS) focused on measuring Myocardial ischemia, Randomized controlled trial, Blinded, Noncardiac surgery, Cardiovascular events, Myocardial injury after non-cardiac surgery, Perioperative myocardial injury, Perioperative myocardial infarction, Perioperative medicine, Heart rate, Ivabradine, Cardiovascular Diseases, Troponin, Perioperative care, Physiological Effects of Drugs, Cardiovascular Agents, Cardiac Chronotropy, Heart Rate Control

Eligibility Criteria

45 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Undergoing noncardiac surgery
  2. ≥45 years of age
  3. Expected to require at least an overnight hospital admission after surgery
  4. Provide written informed consent to participate in the PREVENT-MINS Trial, AND
  5. Fulfill ≥1 of the following 5 criteria (A-E):

A. History of coronary artery disease B. History of peripheral arterial disease C. History of stroke D. Undergoing major vascular surgery, OR

E. Any 3 of 9 risk criteria:

i. Undergoing major surgery ii. History of congestive heart failure iii. History of a transient ischaemic attack iv. Diabetes and currently taking an oral hypoglycemic agent or insulin v. Age ≥70 years vi. History of hypertension vii. Serum creatinine >175 µmol/L (>2.0 mg/dl) viii. History of smoking within 2 years of surgery ix. Undergoing emergent/urgent surgery

Exclusion Criteria:

  1. Conduction abnormalities:

    A. Non-sinus rhythm on ECG B. Sinoatrial or AV (2nd and 3d degree) blocks C. Sick sinus syndrome D. Long QT syndrome E. Pacemaker dependent

  2. Transplanted heart (or on waiting list)
  3. Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil
  4. Resting heart rate <65 beats per minute on the day of surgery
  5. Systolic blood pressure <90 mmHg on the day of surgery
  6. Acute decompensated heart failure, cardiogenic shock, acute myocarditis
  7. Acute coronary syndrome within 2 months before surgery;
  8. Stroke or transient cerebral ischaemia within 1 month before surgery
  9. Known severe liver or kidney disease (MDRD creatinine clearance <15 mL/min)
  10. Inability to tolerate oral intake
  11. Recent use of ivabradine (<1 month)
  12. Known allergy or hypersensitivity to ivabradine
  13. Low-risk surgical procedure based on individual physician's judgment
  14. Investigator considers the patient unreliable regarding requirement for study compliance
  15. Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding
  16. Previously enrolled in the PREVENT-MINS study

Sites / Locations

  • Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza w Bydgoszczy
  • Specjalistyczny Szpital Wojewódzki w CiechanowieRecruiting
  • ZZOZ Szpital Śląski w CieszynieRecruiting
  • Uniwersyteckie Centrum Kliniczne im. Prof. Kornela Gibińskiego Śląski Uniwersytet MedycznyRecruiting
  • Szpital Specjalistyczny św. Łukasza w Końskich
  • Szpital św. Rafała w KrakowieRecruiting
  • 5 Wojskowy Szpital Kliniczny z Polikliniką Samodzielny Publiczny Zakład Opieki Zdrowotnej w KrakowieRecruiting
  • Szpital Zakonu Bonifratrów św. Jana Grandego w KrakowieRecruiting
  • Krakowski Szpital Specjalistyczny im. Jana Pawła IIRecruiting
  • SP ZOZ Szpital Uniwersytecki w KrakowieRecruiting
  • Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie sp. z o.o.Recruiting
  • Szpital Specjalistyczny im. Stefana Żeromskiego w KrakowieRecruiting
  • Samodzielny Publiczny Szpital Kliniczny 1 w LublinieRecruiting
  • Wojewódzki Szpital Specjalistyczny w OlsztynieRecruiting
  • Uniwersytecki Szpital Kliniczny w OpoluRecruiting
  • Samodzielny Publiczny Szpital Kliniczny Nr 2 Pomorskiego Uniwersytetu Medycznego
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu MedycznegoRecruiting
  • Specjalistyczny Szpital im. Edwarda Szczeklika w TarnowieRecruiting
  • Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Szpital Kliniczny Dzieciątka JezusRecruiting
  • Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Centralny Szpital Kliniczny
  • Wojskowy Instytut Medyczny Centralny Szpital Kliniczny MONRecruiting
  • Uniwersytecki Szpital Kliniczny we WrocławiuRecruiting
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanisława Szyszko Śląskiego Uniwersytetu Medycznego w KatowicachRecruiting
  • Szpital Uniwersytecki im. Karola Marcinkowskiego w Zielonej GórzeRecruiting
  • Centralny Szpital Kliniczny Uniwersytetu Medycznego w ŁodziRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Ivabradine

Placebo

Arm Description

Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.

Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.

Outcomes

Primary Outcome Measures

MINS
Number of patients who experience myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery.

Secondary Outcome Measures

A composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest
Number of patients who have at least one of the following: vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest
MINS not fulfilling the 4th universal definition of myocardial infarction
Number of patients who experience MINS not fulfilling the 4th universal definition of myocardial infarction
Myocardial infarction
Number of patients who experience a myocardial infarction
Vascular death
Number of patients who die of vascular cause
Stroke
Number of patients who experience a stroke
All-cause mortality
Number of patients who die of any cause
Days alive and at home
Average number of days when a patient is alive and out of hospital within 30 days after randomization
Health-related quality of life
Average health-related quality of life (based on EuroQol 5 Dimension, five-level version [EQ-5D])
Clinically important atrial fibrillation
Number of patients who experience clinically important atrial fibrillation
Clinically significant bradycardia
Number of patients who experience clinically significant bradycardia
Clinically significant hypotension
Number of patients who experience clinically significant hypotension
Phosphenes
Number of patients who experience phosphenes
Cancellation or postponement of surgery due to concerns about patient's heart rate
Number of surgeries cancelled or postponed due to heart rate concerns
Peak troponin concentration
Peak troponin concentration during the index hospitalization
Area under the curve troponin
Area under the curve of troponin concentrations measured during the hospitalization
Intraoperative mean arterial pressure
Intraoperative mean arterial pressure measured during the index surgery to calculate the average intraoperative mean arterial pressure
Intraoperative heart rate
Intraoperative heart rate measured during the index surgery to calculate the average heart rate

Full Information

First Posted
March 4, 2022
Last Updated
June 1, 2023
Sponsor
Jagiellonian University
Collaborators
Population Health Research Institute, Vanderbilt University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05279651
Brief Title
Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)
Acronym
PREVENT-MINS
Official Title
Ivabradine for PREVENTion of Myocardial Injury After Noncardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 13, 2022 (Actual)
Primary Completion Date
March 15, 2025 (Anticipated)
Study Completion Date
March 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jagiellonian University
Collaborators
Population Health Research Institute, Vanderbilt University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is a multicentre, randomized controlled trial of ivabradine versus placebo.
Detailed Description
The PREVENT-MINS study is a 2,500 patient multicentre, superiority randomized controlled trial of ivabradine versus placebo. The primary objective of the trial is to determine the impact of ivabradine versus placebo on the risk of MINS in patients with or at risk of atherosclerotic disease who are followed for 30 days after noncardiac surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Injury After Noncardiac Surgery (MINS), Myocardial Ischemia
Keywords
Myocardial ischemia, Randomized controlled trial, Blinded, Noncardiac surgery, Cardiovascular events, Myocardial injury after non-cardiac surgery, Perioperative myocardial injury, Perioperative myocardial infarction, Perioperative medicine, Heart rate, Ivabradine, Cardiovascular Diseases, Troponin, Perioperative care, Physiological Effects of Drugs, Cardiovascular Agents, Cardiac Chronotropy, Heart Rate Control

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ivabradine
Arm Type
Active Comparator
Arm Description
Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
Intervention Type
Drug
Intervention Name(s)
Ivabradine
Intervention Description
Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive 5mg of oral ivabradine at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive 5mg oral ivabradine twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Patients fulfilling haemodynamic requirements (i.e. systolic blood pressure ≥90 mmHg and sinus rhythm with a heart rate ≥65 beats per minute) will receive matching placebo at least 1 hour before surgery and the first postoperative dose in the evening or in the morning after surgery, at least 12 hours after the preoperative dose. Starting on the day after surgery, patients will receive matching placebo twice a day and continue this treatment for 7 days after surgery or until hospital discharge.
Primary Outcome Measure Information:
Title
MINS
Description
Number of patients who experience myocardial injury after non-cardiac surgery (MINS) defined as any myocardial infarction and any elevated postoperative cardiac troponin judged as resulting from myocardial ischaemia during or within 30 days after noncardiac surgery.
Time Frame
30 days after randomization
Secondary Outcome Measure Information:
Title
A composite of vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest
Description
Number of patients who have at least one of the following: vascular death, non-fatal MINS, non-fatal stroke, and non-fatal cardiac arrest
Time Frame
30 days after randomization
Title
MINS not fulfilling the 4th universal definition of myocardial infarction
Description
Number of patients who experience MINS not fulfilling the 4th universal definition of myocardial infarction
Time Frame
30 days after randomization
Title
Myocardial infarction
Description
Number of patients who experience a myocardial infarction
Time Frame
30 days after randomization
Title
Vascular death
Description
Number of patients who die of vascular cause
Time Frame
30 days after randomization
Title
Stroke
Description
Number of patients who experience a stroke
Time Frame
30 days after randomization
Title
All-cause mortality
Description
Number of patients who die of any cause
Time Frame
30 days after randomization
Title
Days alive and at home
Description
Average number of days when a patient is alive and out of hospital within 30 days after randomization
Time Frame
30 days after randomization
Title
Health-related quality of life
Description
Average health-related quality of life (based on EuroQol 5 Dimension, five-level version [EQ-5D])
Time Frame
30 days after randomization
Title
Clinically important atrial fibrillation
Description
Number of patients who experience clinically important atrial fibrillation
Time Frame
30 days after randomization
Title
Clinically significant bradycardia
Description
Number of patients who experience clinically significant bradycardia
Time Frame
30 days after randomization
Title
Clinically significant hypotension
Description
Number of patients who experience clinically significant hypotension
Time Frame
30 days after randomization
Title
Phosphenes
Description
Number of patients who experience phosphenes
Time Frame
30 days after randomization
Title
Cancellation or postponement of surgery due to concerns about patient's heart rate
Description
Number of surgeries cancelled or postponed due to heart rate concerns
Time Frame
30 days after randomization
Title
Peak troponin concentration
Description
Peak troponin concentration during the index hospitalization
Time Frame
30 days after randomization
Title
Area under the curve troponin
Description
Area under the curve of troponin concentrations measured during the hospitalization
Time Frame
30 days after randomization
Title
Intraoperative mean arterial pressure
Description
Intraoperative mean arterial pressure measured during the index surgery to calculate the average intraoperative mean arterial pressure
Time Frame
30 days after randomization
Title
Intraoperative heart rate
Description
Intraoperative heart rate measured during the index surgery to calculate the average heart rate
Time Frame
30 days after randomization
Other Pre-specified Outcome Measures:
Title
Cardiac revascularization
Description
Number of patients who undergo cardiac revascularization
Time Frame
30 days after randomization
Title
Re-hospitalization for vascular reasons
Description
Number of patients re-hospitalized for vascular reasons
Time Frame
30 days after randomization
Title
Acute myocardial injury according to Fourth Universal Definition of Myocardial Infarction
Description
Number of patients who experience an acute myocardial injury according to Fourth Universal Definition of Myocardial Infarction
Time Frame
30 days after randomization
Title
Non-fatal cardiac arrest
Description
Number of patients who experience non-fatal cardiac arrest
Time Frame
30 days after randomization
Title
Acute congestive heart failure
Description
Number of patients who experience acute congestive heart failure
Time Frame
30 days after randomization
Title
Any symptomatic or asymptomatic episode of deep vein thrombosis or pulmonary embolism
Description
Number of patients who experience any (symptomatic or asymptomatic) episode of deep vein thrombosis or pulmonary embolism
Time Frame
30 days after randomization
Title
International Society on Thrombosis and Haemostasis (ISTH) major bleeding
Description
Number of patients who experience major bleeding (as defined by ISTH)
Time Frame
30 days after randomization
Title
BIMS
Description
Number of patients who experience bleeding independently associated with mortality after noncardiac surgery (BIMS)
Time Frame
30 days after randomization
Title
Infection/Sepsis
Description
Number of patients who experience infection/sepsis
Time Frame
30 days after randomization
Title
Acute kidney injury fulfilling Kidney Disease Improving Global Outcomes (KDIGO) criteria
Description
Number of patients who experience an acute kidney injury (fulfilling KDIGO criteria)
Time Frame
30 days after randomization
Title
Acute kidney injury requiring dialysis
Description
Number of patients who experience an acute kidney injury requiring dialysis
Time Frame
30 days after randomization
Title
Amputation
Description
Number of patients who undergo an amputation
Time Frame
30 days after randomization
Title
Days outside of intensive care unit
Description
Average number of days alive outside of intensive care/cardiac care unit within 30 days after randomization
Time Frame
30 days after randomization
Title
Length of hospital stay
Description
Average length of hospital stay
Time Frame
30 days after randomization
Title
Length of intensive care unit stay
Description
Average length of intensive care unit stay
Time Frame
30 days after randomization
Title
Discharge destination from the hospital
Description
Number of patients discharge to home/long-term care facility/other
Time Frame
30 days after randomization
Title
All-cause mortality
Description
Number of patients who die of any cause
Time Frame
1 year after randomization
Title
Vascular death
Description
Number of patients who die of vascular cause
Time Frame
1 year after randomization
Title
Myocardial infarction
Description
Number of patients who experience a myocardial infarction
Time Frame
1 year after randomization
Title
Cardiac revascularization
Description
Number of patients who undergo cardiac revascularization
Time Frame
1 year after randomization
Title
Non-fatal cardiac arrest
Description
Number of patients who experience non-fatal cardiac arrest
Time Frame
1 year after randomization
Title
Stroke
Description
Number of patients who experience a stroke
Time Frame
1 year after randomization
Title
Health-related quality of life
Description
Average health-related quality of life (based on EuroQol 5 Dimension, five-level version [EQ-5D])
Time Frame
1 year after randomization
Title
Amputation
Description
Number of patients who have an amputation
Time Frame
1 year after randomization
Title
Re-hospitalization for vascular reasons
Description
Number of patients who experience a re-hospitalization for vascular reasons
Time Frame
1 year after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Undergoing noncardiac surgery ≥45 years of age Expected to require at least an overnight hospital admission after surgery Provide written informed consent to participate in the PREVENT-MINS Trial, AND Fulfill ≥1 of the following 5 criteria (A-E): A. History of coronary artery disease B. History of peripheral arterial disease C. History of stroke D. Undergoing major vascular surgery, OR E. Any 3 of 9 risk criteria: i. Undergoing major surgery ii. History of congestive heart failure iii. History of a transient ischaemic attack iv. Diabetes and currently taking an oral hypoglycemic agent or insulin v. Age ≥70 years vi. History of hypertension vii. Serum creatinine >175 µmol/L (>2.0 mg/dl) viii. History of smoking within 2 years of surgery ix. Undergoing emergent/urgent surgery Exclusion Criteria: Conduction abnormalities: A. Non-sinus rhythm on ECG B. Sinoatrial or AV (2nd and 3d degree) blocks C. Sick sinus syndrome D. Long QT syndrome E. Pacemaker dependent Transplanted heart (or on waiting list) Use of a selected class I or III antiarrhythmic drug (quinidine, disopyramide, sotalol, ibutilide, amiodarone) or diltiazem/verapamil Resting heart rate <65 beats per minute on the day of surgery Systolic blood pressure <90 mmHg on the day of surgery Acute decompensated heart failure, cardiogenic shock, acute myocarditis Acute coronary syndrome within 2 months before surgery; Stroke or transient cerebral ischaemia within 1 month before surgery Known severe liver or kidney disease (MDRD creatinine clearance <15 mL/min) Inability to tolerate oral intake Recent use of ivabradine (<1 month) Known allergy or hypersensitivity to ivabradine Low-risk surgical procedure based on individual physician's judgment Investigator considers the patient unreliable regarding requirement for study compliance Women of childbearing potential who are not taking effective contraception, pregnant or breast-feeding Previously enrolled in the PREVENT-MINS study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bożena Seczyńska, PhD
Phone
(+48) 124332847
Email
bozena.seczynska@uj.edu.pl
First Name & Middle Initial & Last Name or Official Title & Degree
Eliza Kłosowska-Przybył
Phone
(+48) 124332847
Email
eliza.klosowska-przybyl@uj.edu.pl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Wojciech Szczeklik, Professor
Organizational Affiliation
Centre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College
Official's Role
Principal Investigator
Facility Information:
Facility Name
Szpital Uniwersytecki nr 1 im. dr Antoniego Jurasza w Bydgoszczy
City
Bydgoszcz
ZIP/Postal Code
85-094
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Szpital Uniwersytecki nr 1 Bydgoszcz
Email
badaniakliniczne@jurasza.pl
First Name & Middle Initial & Last Name & Degree
Przemysław Jasiewicz, MD PhD
Facility Name
Specjalistyczny Szpital Wojewódzki w Ciechanowie
City
Ciechanów
ZIP/Postal Code
06-400
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Specjalistyczny Szpital Wojewódzki Ciechanów
Email
sekretariat@szpitalciechanow.com.pl
First Name & Middle Initial & Last Name & Degree
Jacek Milecki, MD
Facility Name
ZZOZ Szpital Śląski w Cieszynie
City
Cieszyn
ZIP/Postal Code
43-400
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ZZOZ Szpital Śląski Cieszyn
Email
sekretariat@szpitalslaski.pl
First Name & Middle Initial & Last Name & Degree
Agnieszka Misiewska-Kaczur, MD, PhD
Facility Name
Uniwersyteckie Centrum Kliniczne im. Prof. Kornela Gibińskiego Śląski Uniwersytet Medyczny
City
Katowice
ZIP/Postal Code
40-752
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Uniwersyteckie Centrum Kliniczne Śląski Uniwersytet Medyczny
Email
badaniakliniczne@uck.katowice.pl
First Name & Middle Initial & Last Name & Degree
Anna Szczepańska, MD, PhD
Facility Name
Szpital Specjalistyczny św. Łukasza w Końskich
City
Końskie
ZIP/Postal Code
26-200
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zespół Opieki Zdrowotnej w Końskich
Email
szpital@zoz.konskie.pl
First Name & Middle Initial & Last Name & Degree
Wojciech Gola, MD PhD
Facility Name
Szpital św. Rafała w Krakowie
City
Kraków
ZIP/Postal Code
30-693
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Szpital św. Rafała Kraków
Email
sekretariat.szpitala@scanmed.pl
First Name & Middle Initial & Last Name & Degree
Jarosław Pawlik, MD,PhD
Facility Name
5 Wojskowy Szpital Kliniczny z Polikliniką Samodzielny Publiczny Zakład Opieki Zdrowotnej w Krakowie
City
Kraków
ZIP/Postal Code
30-901
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wojciech Szczeklik, MD, PhD
Email
sekretariat@5wszk.com.pl
First Name & Middle Initial & Last Name & Degree
Jacek Górka, MD, PhD
Email
sekretariat@5wszk.com.pl
First Name & Middle Initial & Last Name & Degree
Wojciech Szczeklik, MD, PhD
First Name & Middle Initial & Last Name & Degree
Jacek Górka, MD, PhD
Facility Name
Szpital Zakonu Bonifratrów św. Jana Grandego w Krakowie
City
Kraków
ZIP/Postal Code
31-061
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Szpital Zakonu Bonifratrów św. Jana Grandego Kraków
Email
sekretariat@bonifratrzy.krakow.pl
First Name & Middle Initial & Last Name & Degree
Dorota Studzińska, MD, PhD
Facility Name
Krakowski Szpital Specjalistyczny im. Jana Pawła II
City
Kraków
ZIP/Postal Code
31-202
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Krakowski Szpital Specjalistyczny im. Jana Pawła II
Email
biuro@szpitaljp2.krakow.pl
First Name & Middle Initial & Last Name & Degree
Mirosław Ziętkiewicz, MD, PhD
Facility Name
SP ZOZ Szpital Uniwersytecki w Krakowie
City
Kraków
ZIP/Postal Code
31-501
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
SP ZOZ Szpital Uniwersytecki Kraków
Email
badaniakliniczne@su.krakow.pl
First Name & Middle Initial & Last Name & Degree
Mikołaj Przydacz, MD, PhD
Facility Name
Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie sp. z o.o.
City
Kraków
ZIP/Postal Code
31-826
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Szpital Specjalistyczny im. Ludwika Rydygiera Kraków
Email
badaniakliniczne@rydygierkrakow.pl
First Name & Middle Initial & Last Name & Degree
Wojciech Mudyna, MD, PhD
Facility Name
Szpital Specjalistyczny im. Stefana Żeromskiego w Krakowie
City
Kraków
ZIP/Postal Code
31-913
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Szpital Specjalistyczny Stefana Żeromskiego w Krakowie
Email
kancelaria@zeromski-szpital.pl
First Name & Middle Initial & Last Name & Degree
Paweł Jarocki, MD
Facility Name
Samodzielny Publiczny Szpital Kliniczny 1 w Lublinie
City
Lublin
ZIP/Postal Code
20-081
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samodzielny Publiczny Szpital Kliniczny 1 Lublin
Email
szpital@spsk1.lublin.pl
First Name & Middle Initial & Last Name & Degree
Michał Borys, MD, PhD
Facility Name
Wojewódzki Szpital Specjalistyczny w Olsztynie
City
Olsztyn
ZIP/Postal Code
10-561
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wojewódzki Szpital Specjalistyczny Olsztyn
Email
szpital@wss.olsztyn.pl
First Name & Middle Initial & Last Name & Degree
Dariusz Onichimowski, MD, PhD
Facility Name
Uniwersytecki Szpital Kliniczny w Opolu
City
Opole
ZIP/Postal Code
45-401
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Uniwersytecki Szpital Kliniczny Opole
Email
centrum@usk.opole.pl
First Name & Middle Initial & Last Name & Degree
Tomasz Czarnik, MD, PhD
Facility Name
Samodzielny Publiczny Szpital Kliniczny Nr 2 Pomorskiego Uniwersytetu Medycznego
City
Szczecin
ZIP/Postal Code
70-111
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM
Email
badania.kliniczne@spsk2-szczecin.pl
First Name & Middle Initial & Last Name & Degree
Katarzyna Kotfis, MD, PhD
Facility Name
Samodzielny Publiczny Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego
City
Szczecin
ZIP/Postal Code
72-252
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samodzielny Publiczny Szpital Kliniczny Nr 1 PUM
Email
m.wasilewicz@spsk1.szn.pl
First Name & Middle Initial & Last Name & Degree
Joanna Sołek-Pastuszka, MD, PhD
Facility Name
Specjalistyczny Szpital im. Edwarda Szczeklika w Tarnowie
City
Tarnów
ZIP/Postal Code
33-100
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Specjalistyczny Szpital im. Edwarda Szczeklika Tarnów
Email
dyrekcja@ssz.tar.pl
First Name & Middle Initial & Last Name & Degree
Paweł Grudzień, MD
Facility Name
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Szpital Kliniczny Dzieciątka Jezus
City
Warszawa
ZIP/Postal Code
02-005
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
UCK WUM Szpital Dzieciątka Jezus Warszawa
Email
badania.kliniczne@uckwum.pl
First Name & Middle Initial & Last Name & Degree
Janusz Trzebicki, MD PhD
Facility Name
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego Centralny Szpital Kliniczny
City
Warszawa
ZIP/Postal Code
02-097
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Uniwersyteckie Centrum Kliniczne WUM
Email
badania.kliniczne@uckwum.pl
First Name & Middle Initial & Last Name & Degree
Paweł Andruszkiewicz, MD, PhD
Facility Name
Wojskowy Instytut Medyczny Centralny Szpital Kliniczny MON
City
Warszawa
ZIP/Postal Code
04-141
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wojskowy Instytut Medyczny Centralny Szpital Kliniczny MON
Email
badaniakliniczne@wim.wim.pl
First Name & Middle Initial & Last Name & Degree
Marcin Możański, MD, PhD
Facility Name
Uniwersytecki Szpital Kliniczny we Wrocławiu
City
Wrocław
ZIP/Postal Code
50-556
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Uniwersytecki Szpital Kliniczny Wrocław
Email
badaniakliniczne@usk.wroc.pl
First Name & Middle Initial & Last Name & Degree
Waldemar Goździk, MD, PhD
Facility Name
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. Prof. Stanisława Szyszko Śląskiego Uniwersytetu Medycznego w Katowicach
City
Zabrze
ZIP/Postal Code
41-800
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samodzielny Publiczny Szpital Kliniczny Nr 1 UM Katowice
Email
sekretariat@szpital.zabrze.pl
First Name & Middle Initial & Last Name & Degree
Szymon Białka, MD, PhD
Facility Name
Szpital Uniwersytecki im. Karola Marcinkowskiego w Zielonej Górze
City
Zielona Góra
ZIP/Postal Code
65-001
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Szpital Uniwersytecki Zielona Góra
Email
no@szpital.zgora.pl
First Name & Middle Initial & Last Name & Degree
Bartosz Kudliński, MD, PhD
Facility Name
Centralny Szpital Kliniczny Uniwersytetu Medycznego w Łodzi
City
Łódź
ZIP/Postal Code
92-213
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Centralny Szpital Kliniczny Uniwersytetu Medycznego Łódź
Email
ckd@csk.umed.pl
First Name & Middle Initial & Last Name & Degree
Waldemar Machała, MD, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

We'll reach out to this number within 24 hrs